On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

• Published in: The New England journal of medicine Vol. 373; no. 23; pp. 2237 - 2246
• Main Authors: Molina, Jean-Michel, Capitant, Catherine, Spire, Bruno, Pialoux, Gilles, Cotte, Laurent, Charreau, Isabelle, Tremblay, Cecile, Le Gall, Jean-Marie, Cua, Eric, Pasquet, Armelle, Raffi, François, Pintado, Claire, Chidiac, Christian, Chas, Julie, Charbonneau, Pierre, Delaugerre, Constance, Suzan-Monti, Marie, Loze, Benedicte, Fonsart, Julien, Peytavin, Gilles, Cheret, Antoine, Timsit, Julie, Girard, Gabriel, Lorente, Nicolas, Préau, Marie, Rooney, James F, Wainberg, Mark A, Thompson, David, Rozenbaum, Willy, Doré, Veronique, Marchand, Lucie, Simon, Marie-Christine, Etien, Nicolas, Aboulker, Jean-Pierre, Meyer, Laurence, Delfraissy, Jean-François
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 03.12.2015
• Subjects: Acquired immune deficiency syndrome; Adult; AIDS; Anal sex; Antigens; Antiretroviral drugs; Antiretroviral therapy; Condoms; Condoms - utilization; Double-Blind Method; Drug dosages; Drug therapy; Drug Therapy, Combination; Emtricitabine; Emtricitabine - adverse effects; Emtricitabine - therapeutic use; Gays & lesbians; Hepatitis; HIV; HIV Infections - prevention & control; HIV-1; Homosexuality, Male; Human immunodeficiency virus; Humanities and Social Sciences; Humans; Infections; Kaplan-Meier Estimate; Male; Medication Adherence; Men; Mens health; Middle Aged; Pre-Exposure Prophylaxis; Prevention; Prophylaxis; Psychology; Public health; Risk exposure; Risk Factors; Sexual Behavior; Sexually Transmitted Diseases - epidemiology; Tenofovir; Tenofovir - adverse effects; Tenofovir - therapeutic use; Urine; France; Canada; HIV; Preexposure Prophylaxis; prevention
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1506273

In this trial of preexposure prophylaxis with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in men who have sex with men, TDF-FTC was found to be effective in preventing HIV-1 infection when it was taken before sexual activity. The prevention of infection with human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) remains a major public health challenge. 1 Owing to the lack of an effective HIV vaccine, consistent condom use remains the cornerstone of prevention, but biomedical interventions such as male circumcision and the use of antiretroviral drugs for the treatment of HIV infection represent additional prevention strategies. 2 – 5 Among the promising interventions is preexposure prophylaxis, in which antiretroviral drugs are started in HIV-negative persons before potential exposure to the virus. Daily oral preexposure prophylaxis with either tenofovir disoproxil fumarate (TDF) or the combination of TDF and . . .